GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Simcere Pharmaceutical Group Ltd (STU:S2P) » Definitions » Total Equity

Simcere Pharmaceutical Group (STU:S2P) Total Equity : €884.7 Mil (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Simcere Pharmaceutical Group Total Equity?

Simcere Pharmaceutical Group's total equity for the quarter that ended in Jun. 2024 was €884.7 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Simcere Pharmaceutical Group Total Equity Historical Data

The historical data trend for Simcere Pharmaceutical Group's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Simcere Pharmaceutical Group Total Equity Chart

Simcere Pharmaceutical Group Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Equity
Get a 7-Day Free Trial 670.71 897.99 967.84 927.60 927.12

Simcere Pharmaceutical Group Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 967.84 1,166.83 927.60 884.70 927.12

Simcere Pharmaceutical Group Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Simcere Pharmaceutical Group's Total Equity for the fiscal year that ended in Dec. 2023 is calculated as

Total Equity=Total Assets(Q: Dec. 2023 )-Total Liabilities(Q: Dec. 2023 )
=1393.912-466.312
=927.6

Simcere Pharmaceutical Group's Total Equity for the quarter that ended in Jun. 2024 is calculated as

Total Equity=Total Assets(Q: Jun. 2024 )-Total Liabilities(Q: Jun. 2024 )
=1499.927-615.233
=884.7

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Simcere Pharmaceutical Group Total Equity Related Terms

Thank you for viewing the detailed overview of Simcere Pharmaceutical Group's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Simcere Pharmaceutical Group Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Simcere Pharmaceutical Group Ltd (STU:S2P) » Definitions » Total Equity
Comparable Companies
HKSE:00512 HKSE:00867 HKSE:03933 HKSE:06185 HKSE:00570 HKSE:02005 HKSE:01558 HKSE:02186 HKSE:03320 HKSE:01681 ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD XSWX:SDZ HKSE:03692 NSE:DIVISLAB XTAE:TEVA
Traded in Other Exchanges
02096:Hong Kong
Address
No. 699-18, Xuanwu Road, Xuanwu District, Jiangsu, Nanjing, CHN, 210042
Website
https://www.simcere.com
Simcere Pharmaceutical Group Ltd is engaged in the R&D, production, and commercialization of pharmaceuticals focused on generic pharmaceuticals. It has a diversified product portfolio focused on therapeutic areas, including, oncology (including cell therapy), nervous system diseases, autoimmune diseases, and antiinfection. The company's products include Endostar, Enweida, Iremod, Sanbexin and Others.

Simcere Pharmaceutical Group Headlines

No Headlines